In 2017, Xiang Jianping founded ArteryFlow Technology Co., Ltd. in Binjiang, Hangzhou, China. ArteryFlow is committed to providing complete solutions for cardiovascular and cerebrovascular diseases, including screening, identification, diagnosis, surgical planning and the development and production of high-value consumables.

 

From a researcher to an entrepreneur, Jianping Xiang has made considerable and sufficient preparations to maintain critical thinking on the subdivision track of cardio-cerebrovascular diagnosis and treatment based on AI technology.

 

A clear sense of purpose enables theoretical research to achieve practical significance

 

In 2007, Jianping Xiang entered the State University of New York at Buffalo to study for a doctorate in mechanical engineering. The University of Buffalo has a famous stroke and vascular disease research center - Toshiba Stroke and Vascular Research Center (TSVRC). It enjoys a worldwide reputation in the research and treatment of cardiovascular and cerebrovascular diseases.

 

During his doctoral study, Jianping Xiang led the development of AView, a complete solution analysis system for predicting the risk of aneurysm rupture. The system provides a series of automatic processing processes, including image segmentation from the initial image input, aneurysm morphology calculation, blood flow simulation calculation and visualization, and surgical planning. AView is used for clinical research and application in 8 centers around the world.

 

Before returning to China, Jianping Xiang had done a lot of pioneering research in the fields of hemodynamics and intracranial vascular intervention consumables and participated in the establishment of a high-value neurological intervention consumables company with his advisor Professor Siddiqui. This also laid the foundation for Xiang Jianping to return to China and start a business.

 

Move forward in challenges and keep critical thinking

 

In Jianping Xiang view, it's time to return home.

 

In 2017, he founded ArteryFlow Technology Co., Ltd. in Binjiang, Hangzhou, China. At the beginning of its establishment, ArteryFlow won the favor of capital and received tens of millions of angel round investments.

 

For Jianping Xiang, team building is the top priority to run a company well.

 

Many of the core R&D personnel of the ArteryFlow team have similar experiences. They were engaged in learning and research in related fields overseas and have accumulated rich experience in computational fluid dynamics, finite element analysis, computational simulation, artificial intelligence and medical imaging before joining ArteryFlow.

 

"At the beginning, there were only 12 people in the whole company. By the end of 2021, there were 125 people in ArteryFlow." Behind the expansion of the team is the expansion of ArteryFlow commercialization. At the end of 2020, ArteryFlow began to set up a marketing team. At present, the marketing team has about 50 members, close to the proportion of R&D team.

 

ArteryFlow's business model has entered a period of rapid transformation and development. "A total of 12 products have obtained marketing registration certificates issued by the National Medical Products Administration (NMPA), CE of Europe and the FDA of the United States. In the past year, our products in the intracranial field have been used in 150 hospitals in China." Jianping Xiang said complacently.

 

Entering 2022, ArteryFlow has gone through five years. "In the next five years, the primary core goal is to make products better. we will reduce the threshold of cardiovascular and cerebrovascular physical examination, help more people and bring health to more people."

 

From a researcher to an entrepreneur, Jianping Xiang believes that entrepreneurs need to maintain critical thinking. "Critical thinking can constantly guide ourselves to go further in the future."